Form S-3ASR Cogent Biosciences, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Cogent (COGT) PT Raised to $50 at Leerink Partners
November 10, 2025 1:18 PM ESTLeerink Partners analyst Andrew Berens raised the price target on Cogent (NASDAQ: COGT) to $50.00 (from $18.00) while maintaining a Outperform rating.
The analyst comments "This morning, COGT announced topline results for the Ph 3 PEAK trial and hosted a conference call. As a reminder, PEAK evaluated the KIT inhibitor bezuclastinib (bezu) in combination with sunitinib vs sunitinib monotherapy in patients with gastrointerstinal stromal tumors (GIST) after progression on the 1L therapy imatinib. We view the results obtained in the 2L as offering unprecedented efficacy... More
Stifel Upgrades Cogent (COGT) to Buy
November 10, 2025 10:54 AM ESTStifel analyst Laura Prendergast upgraded Cogent (NASDAQ: COGT) from Hold to Buy with a price target of $40.00 (from $16.00).
The analyst comments "Today, COGT reported overwhelmingly positive results in the Ph3 PEAK study of bezuclastinib plus sunitinib vs. sunitinib alone in 2L GIST... More
Cogent Biosciences (COGT) files mixed shelf
November 7, 2025 4:53 PM ESTCogent Biosciences (NASDAQ: COGT) has filed mixed shelf of:
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS
... More